These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 25116004)

  • 1. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.
    Schernthaner G; Mogensen CE; Schernthaner GH
    Diab Vasc Dis Res; 2014 Sep; 11(5):306-23. PubMed ID: 25116004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH; Udell JA; Filion KB
    Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.
    Takenaka T; Kishimoto M; Ohta M; Tomonaga O; Suzuki H
    Diab Vasc Dis Res; 2017 May; 14(3):258-261. PubMed ID: 28467199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
    Nicotera R; Casarella A; Longhitano E; Bolignano D; Andreucci M; De Sarro G; Cernaro V; Russo E; Coppolino G
    Pharmacol Res; 2020 Sep; 159():105019. PubMed ID: 32553713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
    Tong L; Adler S
    Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.
    Vallon V; Docherty NG
    Exp Physiol; 2014 Sep; 99(9):1140-5. PubMed ID: 25085841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.
    Cao H; Liu T; Wang L; Ji Q
    Diabetes Obes Metab; 2022 Aug; 24(8):1448-1457. PubMed ID: 35665989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study.
    Kim YG; Byun J; Yoon D; Jeon JY; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    J Diabetes Res; 2016; 2016():1423191. PubMed ID: 28119930
    [No Abstract]   [Full Text] [Related]  

  • 16. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
    Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS
    J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.
    Tsimihodimos V; Filippatos TD; Filippas-Ntekouan S; Elisaf M
    Curr Vasc Pharmacol; 2017; 15(2):96-102. PubMed ID: 27748201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
    Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):388-400. PubMed ID: 33789035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.